Sign in

You're signed outSign in or to get full access.

Lisa Hannusch

Director at CRAWFORD &
Board

About Lisa G. Hannusch

Independent director of Crawford & Company since May 8, 2019 (age 61). She is Managing Member and CEO of Rhino Results, LLC (founded 2017), and previously owned and led UniMed Direct (2004–2017), a medical management software and services firm acquired by Mitchell International in 2017. Her career spans 30+ years in claims services, medical, regulatory, and insurance adjacencies; advisory roles include Cadence Rx (PBM), Bailey Group (private equity), Little Tesoros Therapy Services, and service on the National Board of Governors for the Human Rights Campaign .

Past Roles

OrganizationRoleTenureCommittees/Impact
Rhino Results, LLCManaging Member & CEO“Currently”; founded in 2017Strategy consulting and investments in healthcare/insurance-related industries
UniMed DirectOwner & CEO2004–2017Led medical management software and services; company purchased by Mitchell International in 2017

External Roles

OrganizationRoleTypeNotes
Cadence RxAdvisory Board MemberPrivate company (PBM)Advisory capacity
Bailey GroupAdvisory Board MemberPrivate equity firmAdvisory capacity
Little Tesoros Therapy ServicesAdvisory Board MemberPediatric therapy clinicsAdvisory capacity
Human Rights CampaignNational Board of GovernorsNon-profitNational governance role

Board Governance

TopicDetail
IndependenceBoard determined all director nominees independent under NYSE standards except the CEO; Hannusch is independent .
Standing CommitteesAudit Committee (member); Governance Committee (member) .
Committee ChairsAudit Chair: Fred R. Donner; Governance Chair: Rahul Patel .
2024 Committee MeetingsAudit: 10 meetings; Governance: 4 meetings .
Board Meetings & AttendanceBoard held 5 meetings in 2024; each current director attended at least 75% of Board and committee meetings of which they were a member .
Executive SessionsIndependent directors met 5 times in 2024; presided over by Non-Executive Chair Jesse C. Crawford, Jr. .
Related-Party OversightAudit Committee reviews/approves related-party transactions per written policy; independence determinations consider any related-party transactions .
Leadership StructureChair and CEO roles separated; Board believes separation enhances oversight and independence .

Fixed Compensation

Element2024 Value
Annual cash retainer (paid quarterly)$50,000
Board meeting fees (per meeting)$1,500
Committee meeting fees (per meeting)$1,500
Restricted share award (granted annually)$90,000
Chair retainers (if applicable)Audit Chair $25,000; Comp & HC Chair $15,000; Governance Chair $12,500; Executive Committee Chair $12,000; Board Chair $100,000
Lisa G. Hannusch – 2024 Director CompensationAmount
Fees earned or paid in cash$81,500
Stock awards (grant-date fair value, ASC 718)$89,990
Option awards
All other compensation
Total$171,490
NoteRestricted share awards granted to Directors in 2024 vested in full on December 31, 2024

Performance Compensation

ComponentDetail
Equity vehicleRestricted share award (non-employee director)
Grant-date fair value (2024)$89,990
VestingVested in full on December 31, 2024
Performance metricsNone disclosed for director equity; awards are time-based (no PSU/options for directors in 2024)

Other Directorships & Interlocks

CategoryDetail
Current public company boardsNot disclosed for Hannusch in the proxy biography (advisory and non-profit roles noted) .
Compensation Committee interlocksThe CHC Committee members are Beale (Chair), J. C. Crawford, Murphy, and Donner; interlocks disclosure reports none; Hannusch is not on this committee .

Expertise & Qualifications

  • 30+ years in claims services, medical, regulatory, and insurance-adjacent sectors; founder/operator background (UniMed Direct), and ongoing consulting/investment leadership (Rhino Results) .
  • Governance experience via Audit Committee (financial reporting, internal controls, cybersecurity oversight) and Governance Committee (ERM oversight, compliance/ethics, board succession) .

Equity Ownership

HolderClass A SharesClass B Shares% of Class A Outstanding% of Class B Outstanding
Lisa G. Hannusch72,691 <1%
Stock Ownership Guidelines (Directors)Status
Requirement$200,000 in value or 25,000 shares (2024)
ComplianceAll current non-employee directors comply, except Donner (grace to Nov 2, 2025) and Murphy (grace to Jun 25, 2026); implies Hannusch is in compliance

Governance Assessment

  • Independent, experienced operator-investor with sector-relevant expertise; sits on Audit and Governance—two high-impact committees for financial reporting integrity and governance/ERM—supporting board effectiveness .
  • Strong engagement signals: Board met 5x; Audit 10x; Governance 4x; independent directors held 5 executive sessions; each current director attended at least 75% of applicable meetings; nominees (except Murphy) attended the 2024 annual meeting, indicating commitment .
  • Pay and alignment: 2024 mix balanced between cash ($81.5k) and equity ($89.99k), with full-year vesting and compliance with director ownership guidelines, aligning with shareholders without risk-inducing option grants .
  • Conflicts/controls: Audit Committee oversees related-party transactions; Board expressly considered related-party matters in independence determinations; no specific related-party transactions involving Hannusch are disclosed in the cited sections .
  • Structural context: Separation of Chair/CEO is a positive governance feature; however, the company remains controlled by the Crawford family (e.g., Jesse C. Crawford owns 67.7% of Class B), a factor investors should monitor for potential minority-shareholder risk despite independent oversight .
  • Compliance hygiene: The company reports timely Section 16(a) beneficial ownership filings by officers/directors and >10% holders for 2024, reducing procedural red-flag risk .